OVERVIEW

Penn Neuromuscular Symposium 2027 is organized by Penn Medicine - Continuing Medical and Interprofessional Education and will be held on Mar 13, 2027 at Smilow Center for Translational Research, Philadelphia, Pennsylvania, United States of America.

Course Overview:
This full-day program features:

  • Expert-led lectures covering the breadth of neuromuscular disease, including neuropathies, myopathies, motor neuron disease, and neuromuscular junction disorders
  • Treatment updates on emerging therapies, newly approved agents, and evolving management strategies
  • Interactive case conferences presenting complex, real-world clinical scenarios to sharpen diagnostic reasoning and therapeutic decision-making

Designed to reflect the latest advances in the field, this symposium equips attendees with practical, evidence-based knowledge directly applicable to patient care, making it an essential event for clinicians at every stage of their career.

The Symposium will also explain how to enhance collaboration and knowledge exchange among neurologists and other healthcare professionals taking care of this unique patient population, which will also help facilitate enrollment in exciting clinical trials.

Objectives:
After completing this activity, participants should be able to:

  1. Review novel treatments for spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), including recently approved therapies and emerging clinical trial data.
  2. Discuss emerging therapies and evolving standards of care for autoimmune neuropathies.
  3. Describe recent advances in the diagnosis and treatment of hereditary neuropathies and hATTR amyloidosis.
  4. Discuss challenging clinical cases to enhance diagnostic reasoning and management strategies in neuromuscular disorders.
  5. Explain current approaches to the diagnosis and targeted treatment of autoimmune myopathies.
  6. Evaluate the role and recent advances of gene therapy in the treatment of neuromuscular diseases.
  7. Describe the evolving treatment landscape for hereditary muscular dystrophies, including newly approved and emerging therapies.
  8. Describe novel immunotherapies for myasthenia gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS) and their mechanisms of action.
  9. Interpret antibody testing in Guillain-Barré Syndrome (GBS), CIDP, and autoimmune neuropathies, including clinical pearls and pitfalls.

KEY DATES

Registrations Open
10 Nov, 2026
Registrations Open
Event Start Date
13 Mar, 2027
Event Start Date
Event End Date
13 Mar, 2027
Event End Date
Credits

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit:
Physicians: Penn Medicine designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This program provides 6.00 NCPD Hours.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 6.00 Category 1 credits for completing this activity. 

  • 6 AMA PRA Category 1 Credits™
  • 6 Credits
  • 6 Hours
  • TARGET AUDIENCE

    PhysicianPhysician AssistantCliniciansStudentsNeurologistsAllied Health ProfessionalsNurse Practitioners Other Healthcare ProfessionalsRegistered Nurse

    SPECIALITIES

    Neurology

    SUGGESTED HOTELS

    CONFERENCE VENUE

    LocationSmilow Center for Translational Research
    Arthur H. Rubenstein Auditorium at the Smilow Center for Translational Research

    RELATED CONFERENCES & LIVE WEBINARS